Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intellia Therapeutics (NTLA – Research Report), Pediatrix Medical Group (MD – Research Report) and LAVA Therapeutics (LVTX – Research Report).
Intellia Therapeutics (NTLA)
SVB Securities analyst Mani Foroohar maintained a Buy rating on Intellia Therapeutics on June 12. The company’s shares closed last Tuesday at $46.03.
According to TipRanks.com, Foroohar is ranked 0 out of 5 stars with an average return of
Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $84.00, implying an 89.9% upside from current levels. In a report issued on June 8, Bank of America Securities also maintained a Buy rating on the stock with a $89.00 price target.
See the top stocks recommended by analysts >>
Pediatrix Medical Group (MD)
SVB Securities analyst Whit Mayo maintained a Hold rating on Pediatrix Medical Group yesterday and set a price target of $14.00. The company’s shares closed last Tuesday at $14.24, close to its 52-week low of $12.84.
According to TipRanks.com, Mayo is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Pediatrix Medical Group with a $14.50 average price target.
LAVA Therapeutics (LVTX)
In a report issued on June 12, Daina Graybosch from SVB Securities maintained a Buy rating on LAVA Therapeutics, with a price target of $28.00. The company’s shares closed last Tuesday at $2.38.
According to TipRanks.com, Graybosch ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on LAVA Therapeutics is a Strong Buy with an average price target of $12.75, which is a 435.7% upside from current levels. In a report issued on June 12, H.C. Wainwright also maintained a Buy rating on the stock with a $9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NTLA:
- Intellia Rises on Promising Phase 1 Data in Hereditary Angioedema
- Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
- Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023
- Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities
